Core Viewpoint - Southbound funds have significantly reduced their holdings in Hema Medical (03309.HK), indicating a bearish sentiment towards the company in recent trading days [1]. Group 1: Shareholding Changes - On November 6, southbound funds reduced their holdings by 58,000 shares, marking a decrease of 0.07% [2]. - Over the past five trading days, there has been a cumulative net reduction of 1,252,000 shares, with reductions occurring on all five days [1][2]. - In the last twenty trading days, the total net reduction reached 3,934,000 shares, with reductions on all twenty days [1]. Group 2: Current Holdings - As of the latest data, southbound funds hold 77,831,000 shares of Hema Medical, which represents 6.19% of the company's total issued ordinary shares [1][2]. Group 3: Company Overview - Hema Medical Holdings Limited primarily engages in providing medical services through four divisions: Hong Kong medical services, mainland dental services, medical consumables sales, and mainland ophthalmic services [2].

Core Viewpoint - Southbound funds have significantly reduced their holdings in Hema Medical (03309.HK), indicating a bearish sentiment towards the company in recent trading days [1]. Summary by Sections Southbound Fund Holdings - On October 22, southbound funds reduced their holdings by 72,000 shares, marking a decrease of 0.09% [2]. - Over the past five trading days, there has been a cumulative net reduction of 634,000 shares, with reductions occurring on all five days [1][2]. - In the last 20 trading days, the total net reduction reached 3,286,000 shares, with reductions on all 20 days [1]. Current Holdings - As of the latest data, southbound funds hold a total of 79,449,000 shares of Hema Medical, which represents 6.32% of the company's total issued ordinary shares [1][2]. Company Overview - Hema Medical Holdings Limited primarily engages in providing medical services through four divisions: - The Hong Kong medical division focuses on ophthalmology, dentistry, and other medical services, as well as the sale of vision aids [2]. - The mainland dental division provides dental services in mainland China [2]. - The medical consumables division sells medical consumables in Hong Kong [2]. - The mainland ophthalmology division offers ophthalmic services and sells vision aids in mainland China [2].

Core Viewpoint - Southbound funds have significantly reduced their holdings in Hema Medical (03309.HK), indicating a bearish sentiment towards the company in recent trading days [1]. Summary by Sections Southbound Fund Holdings - On October 15, southbound funds reduced their holdings by 88,000 shares, marking a decrease of 0.11% [2]. - Over the past five trading days, there has been a cumulative net reduction of 1,242,000 shares, with reductions occurring on all five days [1][2]. - In the last 20 trading days, the total net reduction reached 3,440,000 shares, with reductions on all 20 days [1]. Current Holdings - As of now, southbound funds hold 80,083,000 shares of Hema Medical, which represents 6.37% of the company's total issued ordinary shares [1]. Company Overview - Hema Medical Holdings Limited primarily engages in providing medical services through four divisions: - The Hong Kong medical division focuses on ophthalmology, dentistry, and other medical services, along with the sale of vision aids [2]. - The mainland dental division provides dental services in mainland China [2]. - The medical consumables sales division operates in Hong Kong [2]. - The mainland ophthalmology division offers ophthalmic services and sells vision aids in mainland China [2].

Core Viewpoint - 盈健医疗 (01419) reported a revenue of approximately HKD 644.4 million for the year ending June 30, 2025, reflecting a year-on-year increase of about 9.1% [1] - The profit attributable to shareholders was approximately HKD 26.3 million, representing a year-on-year growth of about 8.9% [1] - Basic earnings per share were approximately HKD 0.069, with a final dividend of HKD 0.03 [1] Revenue Growth - The increase in profit was primarily driven by growth in revenue from general medical services, specialized medical services, and dental services [1] - The gross profit also increased, attributed to the overall revenue growth [1]

Core Viewpoint - 盈健医疗 (01419.HK) reported a revenue of approximately HKD 644 million for the fiscal year 2025, reflecting a year-on-year increase of about 9.1% [1] - The profit attributable to the company's owners was approximately HKD 26.3 million, representing a year-on-year increase of about 8.9% [1] - The board proposed a final dividend of HKD 0.03 per share for the fiscal year 2025, up from HKD 0.028 in fiscal year 2024 [1] Revenue and Profit Growth - The company achieved a steady revenue growth despite ongoing adverse economic conditions in Hong Kong, with a revenue increase of approximately 9.1% compared to fiscal year 2024 [1] - The profit attributable to the owners increased by about 8.9% year-on-year, indicating strong financial performance [1] Business Segment Performance - The core business segments maintained balanced growth, with the primary care division showing stable performance driven by network expansion and a strong patient base [1] - The specialty medical division experienced robust revenue growth due to service upgrades and the addition of more specialists, particularly in ophthalmology, pediatric surgery, cardiology, psychiatry, and orthopedics [1] - Despite competitive pressures in the dental segment, overall revenue growth was achieved following the acquisition of Youde Dental in fiscal year 2025 [1]

Core Viewpoint - Yingjian Medical (01419) reported a revenue of approximately HKD 644.4 million for the year ending June 30, 2025, reflecting a year-on-year increase of about 9.1% [1] - The profit attributable to the company's owners was approximately HKD 26.3 million, representing a year-on-year growth of about 8.9% [1] - Basic earnings per share were approximately HKD 0.069, with a final dividend of HKD 0.03 [1] Revenue Growth - The increase in profit was primarily driven by growth in general medical services, specialized medical services, and dental services [1] - Gross profit increased due to the rise in revenue [1]

Core Viewpoint - Modern Dental Group reported a revenue of HKD 1.835 billion for the six months ending June 30, 2025, representing a year-on-year increase of 7.81% [1] - The profit attributable to the company's owners was HKD 285 million, a significant year-on-year increase of 32.52% [1] - The company plans to distribute an interim dividend of HKD 0.107 per share [1] Revenue Growth Drivers - The revenue growth was primarily driven by sustained organic growth in Europe and Australia [1] - The completion of the acquisition of Thailand's largest dental laboratory, Hexa Ceram Company Limited, in January 2025 accelerated the group's growth [1]

Core Viewpoint - Hema Medical (03309) reported a revenue increase of 2.4% year-on-year, driven by rising demand for ophthalmic medical services in Hong Kong, despite competitive pressures in Shenzhen affecting dental and ophthalmic service revenues [1] Financial Performance - Revenue for the first half of 2025 reached HKD 944 million, reflecting a year-on-year growth of 2.4% [1] - Profit attributable to equity holders amounted to HKD 49.94 million, showing a significant year-on-year increase of 62.4% [1] Market Dynamics - The growth in revenue was primarily attributed to increased demand for ophthalmic services in the Hong Kong market, which was partially offset by decreased revenues in Shenzhen due to intense competition in dental and ophthalmic services [1] Acquisition Announcement - Hema Medical announced the acquisition of 58% of the issued share capital of Hong Kong Endoscopy Examination and Treatment Centre Limited, which operates under the name "Hong Kong Endoscopy Centre" [1] - The acquisition is expected to be completed around October 2025 [1]

Core Viewpoint - Hema Medical (03309) reported a 6.5% increase in stock price, reaching HKD 2.13, with a trading volume of HKD 6.7167 million following the release of its mid-year results for 2025 [1] Financial Performance - The company reported revenue of HKD 944 million for the first half of 2025, representing a year-on-year growth of 2.4% [1] - Profit attributable to equity holders was HKD 49.944 million, showing a significant year-on-year increase of 62.4% [1] Market Dynamics - The slight increase in revenue was attributed to rising demand for ophthalmic medical services in Hong Kong, which boosted revenue from ophthalmic services [1] - However, this growth was partially offset by a decline in revenue from dental and ophthalmic services in Shenzhen due to intense competition [1] Acquisition Announcement - Hema Medical announced an agreement to acquire 58% of the issued share capital of Hong Kong Endoscopy Examination and Treatment Centre Limited, which operates under the name "Hong Kong Endoscopy Centre" [1] - The acquisition is expected to be completed around October 2025 [1]

Core Viewpoint - The company reported a slight increase in revenue driven by the growing demand for ophthalmic medical services in Hong Kong, although this was partially offset by a decrease in revenue from dental and ophthalmic services in Shenzhen due to intense competition [1] Financial Performance - Revenue for the six months ending June 30, 2025, was HKD 944 million, representing a year-on-year growth of 2.4% [1] - Profit attributable to equity holders was HKD 49.944 million, showing a significant year-on-year increase of 62.4% [1] - Basic earnings per share were HKD 0.0411 [1] Market Dynamics - The increase in revenue was primarily attributed to the rising demand for ophthalmic services in the Hong Kong market [1] - The decline in revenue from Shenzhen's dental and ophthalmic services was a result of fierce competition in that region [1]